Crystal structure of a 1:1 co-crystal of the anticancer drug gefitinib with azelaic acid

In the title co-crystal, C22H24ClFN4O3·C9H16O4, gefitinib (GTB; systematic name: quinazolin-4-amine) co-crystallizes with azelaic acid (AA; systematic name: nonanedioic acid). The co-crystal has the monoclinic P21/n centrosymmetric space group, containing one molecule each of GTB and AA in the asymm...

Full description

Bibliographic Details
Main Authors: Christy P. George, Ekta Sangtani, Rajesh G. Gonnade
Format: Article
Language:English
Published: International Union of Crystallography 2020-06-01
Series:Acta Crystallographica Section E: Crystallographic Communications
Subjects:
Online Access:http://scripts.iucr.org/cgi-bin/paper?S2056989020006623
Description
Summary:In the title co-crystal, C22H24ClFN4O3·C9H16O4, gefitinib (GTB; systematic name: quinazolin-4-amine) co-crystallizes with azelaic acid (AA; systematic name: nonanedioic acid). The co-crystal has the monoclinic P21/n centrosymmetric space group, containing one molecule each of GTB and AA in the asymmetric unit. A structure overlay of the GTB molecule in the co-crystal with that of its most stable polymorph revealed a significant difference in the conformation of the morpholine moiety. The significant deviation in the conformation of one of the acidic groups of azelaic acid from its usual linear chain structure could be due to the encapsulation of one acidic group in the pocket formed between the two pincers of GTB namely, the morpholine and phenyl moieties. Both GTB and AA molecules form N—H...O, O—H...N, C—H...O hydrogen bonds with C—H...F close contacts along with off-stacked aromatic π–π interactions between the GTB molecules.
ISSN:2056-9890